GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.66
+9.45%Margins
Gross margin
92.9%
EBITDA margin
-542.5%
EBIT margin
-633.0%
Net margin
-560.9%
FCF margin
-111.7%
-33.1%
Return on equity
-23.1%
Return on assets
-34.6%
Return on invested capital
0.04x
Asset turnover
-$24.1M
Cash from operations
$7.28
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026